Download MendeleyOptimization of 3-Pyrimidin-4-yl-oxazolidin-2-ones as Allosteric and Mutant Specific Inhibitors of IDH1.
Levell, J.R., Caferro, T., Chenail, G., Dix, I., Dooley, J., Firestone, B., Fortin, P.D., Giraldes, J., Gould, T., Growney, J.D., Jones, M.D., Kulathila, R., Lin, F., Liu, G., Mueller, A., van der Plas, S., Slocum, K., Smith, T., Terranova, R., Toure, B.B., Tyagi, V., Wagner, T., Xie, X., Xu, M., Yang, F.S., Zhou, L.X., Pagliarini, R., Cho, Y.S.(2017) ACS Med Chem Lett 8: 151-156
- PubMed: 28197303
- DOI: https://doi.org/10.1021/acsmedchemlett.6b00334
- Primary Citation of Related Structures:
5TQH - PubMed Abstract:
High throughput screening and subsequent hit validation identified 4-isopropyl-3-(2-((1-phenylethyl)amino)pyrimidin-4-yl)oxazolidin-2-one as a potent inhibitor of IDH1 R132H . Synthesis of the four separate stereoisomers identified the ( S , S )-diastereomer ( IDH125 , 1f ) as the most potent isomer. This also showed reasonable cellular activity and excellent selectivity vs IDH1 wt . Initial structure-activity relationship exploration identified the key tolerances and potential for optimization. X-ray crystallography identified a functionally relevant allosteric binding site amenable to inhibitors, which can penetrate the blood-brain barrier, and aided rational optimization. Potency improvement and modulation of the physicochemical properties identified ( S , S )-oxazolidinone IDH889 ( 5x ) with good exposure and 2-HG inhibitory activity in a mutant IDH1 xenograft mouse model.
Organizational Affiliation:
Novartis Institutes for Biomedical Research , 250 Massachusetts Avenue, Cambridge, Massachusetts 02139, United States.
